6-K 1 d236728d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2021

Commission File Number: 001-39487

 

 

Silence Therapeutics plc

(Exact Name of Registrant as Specified in Its Charter)

 

 

72 Hammersmith Road

London W14 8TH

United Kingdom

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒             Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ☐

 

 

 


Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated November 1, 2021.

Exhibit 99.1 to this Report shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File no. 333-248682) and Form F-3 (File nos. 333-260265 and 333-248203) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

 

Exhibit

No.

   Description
99.1    Regulatory News Announcement, dated November 1, 2021.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Silence Therapeutics plc
By:  

/s/ Mark Rothera

  Name:   Mark Rothera
  Title:   President and Chief Executive Officer

Date: November 1, 2021